FIELD: medicine.
SUBSTANCE: pharmaceutical antitumoral medicinal system includes a biologically inert proto-medicine and biologically inert activation medical product. After the period of delay, which promotes differential concentrating of proto-medicines in tumoral either invasive tissues - or cells-targets, the nontoxic medical product is modified by means of an activation medical product selectively to reach toxic levels of a pharmacologically active agent in target tissues.
EFFECT: new antitumoral system possesses high efficiency and the lowered level of toxicity in comparison with already known systems.
34 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROCYCLIC ANTIBIOTIC DELIVERY TO CANCER CELLS BY MEANS OF NANO-NUCLEOTIDE PHARMACOSOMES | 2008 |
|
RU2372073C1 |
| METHOD OF INDUCING APOPTOSIS OF MALIGNANT TUMOUR CELLS OF COLORECTAL CANCER AND MEANS FOR ITS REALISATION | 2013 |
|
RU2551238C9 |
| CONJUGATE OF ANTIMELANOMA ANTIBODY AND CYTOTOXIC AGENT AND A METHOD OF MELANOMA INHIBITION | 1991 |
|
RU2119352C1 |
| USE OF ALPHAVIRUS IN PREPARATION OF ANTITUMOR DRUGS | 2015 |
|
RU2693938C2 |
| ONCOLYTIC CLOSTRIDIUM GHONII STRAINS, METHODS OF PRODUCTION AND USE | 2013 |
|
RU2667432C2 |
| HIGHLY EFFECTIVE METHOD FOR PREPARING DOSAGE FORM OF TARGETED ACTION FOR THERAPY OF MALIGNANT GROWTHS | 2019 |
|
RU2727924C1 |
| SYNERGIC COMBINATION OF PROTEASOME INHIBITOR AND VITAMIN K FOR INHIBITION OF GROWTH AND PROLIFERATION OF TUMOUR CELLS, PHARMACEUTICAL COMPOSITION AND THEREOF-BASED ANTI-TUMOUR MEDICATION | 2013 |
|
RU2563986C2 |
| CONJUGATE POSSESSING SELECTIVE EFFECT WITH RESPECT TO CANCER TUMORS | 2005 |
|
RU2303997C2 |
| COMPOSITION CONTAINING 1,2,4-BENZOTRIAZINE-3-AMINE-1,4-DIOXIDE FOR PARENTERAL ADMINISTRATION AND METHOD OF TREATMENT WITH ITS USE | 1996 |
|
RU2166946C2 |
| ANTIBODY AGAINST PODOKALIXIN AND TRA-RELATED PROTEIN, METHODS FOR ITS PRODUCTION AND USE AS ANTITUMOR THERAPEUTIC AGENT | 2017 |
|
RU2774710C2 |
